| Side Effect . | Pooled placebo (n=25) . | Pooled active (n=25) . | 1.4 mg (n=3) . | 2.8 mg (n=5) . | 4.6 mg (n=5) . | 6.8 mg (n=6) . | 9.6 mg (n=6) . |
|---|---|---|---|---|---|---|---|
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
| Autonomic | |||||||
| Tachycardia | 1 (4%) | 0 (0%) | – | – | – | – | |
| Bradycardia | 0 (0%) | 1 (4%) | – | 1 (4%) | – | – | – |
| Chest tightness | 2 (8%) | 0 (0%) | – | – | – | – | – |
| CNS/psychiatric | |||||||
| Headache | 2 (8%) | 1 (4%) | – | 1 (4%) | – | – | – |
| Dizziness | 3 (12%) | 0 (0%) | – | – | – | – | – |
| Irritability | 0 (0%) | 1 (4%) | – | – | 1 (4%) | – | – |
| Lightheadedness | 3 (12%) | 0 (0%) | – | – | – | – | – |
| Blurry vision | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Fatigue | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Sleepiness | 2 (8%) | 0 (0%) | – | – | – | – | – |
| Gastrointestinal | |||||||
| Nausea | 0 (0%) | 1 (4%) | 1 (4%) | – | – | – | – |
| Skin disorders | |||||||
| Itchiness | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Other | |||||||
| Flu-like symptoms | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Fever | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Nasal congestion | 0 (0%) | 1 (4%) | – | – | – | – | 1 (4%) |
| Side Effect . | Pooled placebo (n=25) . | Pooled active (n=25) . | 1.4 mg (n=3) . | 2.8 mg (n=5) . | 4.6 mg (n=5) . | 6.8 mg (n=6) . | 9.6 mg (n=6) . |
|---|---|---|---|---|---|---|---|
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
| Autonomic | |||||||
| Tachycardia | 1 (4%) | 0 (0%) | – | – | – | – | |
| Bradycardia | 0 (0%) | 1 (4%) | – | 1 (4%) | – | – | – |
| Chest tightness | 2 (8%) | 0 (0%) | – | – | – | – | – |
| CNS/psychiatric | |||||||
| Headache | 2 (8%) | 1 (4%) | – | 1 (4%) | – | – | – |
| Dizziness | 3 (12%) | 0 (0%) | – | – | – | – | – |
| Irritability | 0 (0%) | 1 (4%) | – | – | 1 (4%) | – | – |
| Lightheadedness | 3 (12%) | 0 (0%) | – | – | – | – | – |
| Blurry vision | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Fatigue | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Sleepiness | 2 (8%) | 0 (0%) | – | – | – | – | – |
| Gastrointestinal | |||||||
| Nausea | 0 (0%) | 1 (4%) | 1 (4%) | – | – | – | – |
| Skin disorders | |||||||
| Itchiness | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Other | |||||||
| Flu-like symptoms | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Fever | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Nasal congestion | 0 (0%) | 1 (4%) | – | – | – | – | 1 (4%) |
n=24 subjects overlapped in both the pooled placebo and pooled active groups, but one subject dropped out after participating in a placebo condition and did not complete an active condition, and another subject dropped out after participating in an active condition and did not complete a placebo condition.
Number of subjects experiencing an adverse event: only events rated “possibly,” “probably,” or “definitely” related to drug were included.
| Side Effect . | Pooled placebo (n=25) . | Pooled active (n=25) . | 1.4 mg (n=3) . | 2.8 mg (n=5) . | 4.6 mg (n=5) . | 6.8 mg (n=6) . | 9.6 mg (n=6) . |
|---|---|---|---|---|---|---|---|
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
| Autonomic | |||||||
| Tachycardia | 1 (4%) | 0 (0%) | – | – | – | – | |
| Bradycardia | 0 (0%) | 1 (4%) | – | 1 (4%) | – | – | – |
| Chest tightness | 2 (8%) | 0 (0%) | – | – | – | – | – |
| CNS/psychiatric | |||||||
| Headache | 2 (8%) | 1 (4%) | – | 1 (4%) | – | – | – |
| Dizziness | 3 (12%) | 0 (0%) | – | – | – | – | – |
| Irritability | 0 (0%) | 1 (4%) | – | – | 1 (4%) | – | – |
| Lightheadedness | 3 (12%) | 0 (0%) | – | – | – | – | – |
| Blurry vision | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Fatigue | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Sleepiness | 2 (8%) | 0 (0%) | – | – | – | – | – |
| Gastrointestinal | |||||||
| Nausea | 0 (0%) | 1 (4%) | 1 (4%) | – | – | – | – |
| Skin disorders | |||||||
| Itchiness | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Other | |||||||
| Flu-like symptoms | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Fever | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Nasal congestion | 0 (0%) | 1 (4%) | – | – | – | – | 1 (4%) |
| Side Effect . | Pooled placebo (n=25) . | Pooled active (n=25) . | 1.4 mg (n=3) . | 2.8 mg (n=5) . | 4.6 mg (n=5) . | 6.8 mg (n=6) . | 9.6 mg (n=6) . |
|---|---|---|---|---|---|---|---|
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
| Autonomic | |||||||
| Tachycardia | 1 (4%) | 0 (0%) | – | – | – | – | |
| Bradycardia | 0 (0%) | 1 (4%) | – | 1 (4%) | – | – | – |
| Chest tightness | 2 (8%) | 0 (0%) | – | – | – | – | – |
| CNS/psychiatric | |||||||
| Headache | 2 (8%) | 1 (4%) | – | 1 (4%) | – | – | – |
| Dizziness | 3 (12%) | 0 (0%) | – | – | – | – | – |
| Irritability | 0 (0%) | 1 (4%) | – | – | 1 (4%) | – | – |
| Lightheadedness | 3 (12%) | 0 (0%) | – | – | – | – | – |
| Blurry vision | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Fatigue | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Sleepiness | 2 (8%) | 0 (0%) | – | – | – | – | – |
| Gastrointestinal | |||||||
| Nausea | 0 (0%) | 1 (4%) | 1 (4%) | – | – | – | – |
| Skin disorders | |||||||
| Itchiness | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Other | |||||||
| Flu-like symptoms | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Fever | 1 (4%) | 0 (0%) | – | – | – | – | – |
| Nasal congestion | 0 (0%) | 1 (4%) | – | – | – | – | 1 (4%) |
n=24 subjects overlapped in both the pooled placebo and pooled active groups, but one subject dropped out after participating in a placebo condition and did not complete an active condition, and another subject dropped out after participating in an active condition and did not complete a placebo condition.
Number of subjects experiencing an adverse event: only events rated “possibly,” “probably,” or “definitely” related to drug were included.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
